Immunocore (IMCR)
(Delayed Data from NSDQ)
$35.29 USD
-0.64 (-1.78%)
Updated Oct 2, 2025 04:00 PM ET
After-Market: $34.93 -0.36 (-1.02%) 5:10 PM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IMCR 35.29 -0.64(-1.78%)
Will IMCR be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for IMCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMCR
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y
IMCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
Other News for IMCR
IMCR falls 1.1% on October 1, leaving the technical picture intact
Crossed Above 20 Day Moving Average appears for IMCR after 5.79% move
Is IMCR positioned for a breakdown? 20 Day Moving Average Resistance shows up after climbing 0.94%
20 Day Moving Average Resistance appears for IMCR after 0.18% move
IMCR forms 50 Day Moving Average Support on September 25